probiotic supplements in the treatment of pregnant women with COVID-19

Phase 3

Recruiting

Conditions: Coronavirus disease in pregnancy.
Other viral diseases complicating pregnancy, childbirth and the puerperium
O98.5

Registration Number: IRCT20080826001096N8

Lead Sponsor: Rasht University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Female

Target Recruitment: 80

Inclusion Criteria

Pregnant women with mild / moderate COVID-19 hospitalization in Al-Zahra Hospital in Rasht
Diagnosis based on a positive PCR or antigen test results
Hospitalization on the day of admission
Onset of Covid symptoms up to 5 days before admission to the study
Gestational age>12 weeks
Age= 16 years
fever (oral temperature =37.2 ° C)
Having at least one of the criteria of respiratory rate=24 per minute or oxygen saturation < 93 (without oxygen) Pa2 / Fi2
Completion of informed consent form

Exclusion Criteria

Existence of any obstetric problems such as premature rupture of the amniotic membrane, placental abruption
History of receiving probiotic supplement for up to one week before enrollment
Presence of underlying diseases and gastrointestinal disorders such as IBD
Presence chronic diseases under treatment (such as asthma and allergies, heart failure) and acquired or congenital immunodeficiencies

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration from the start of the study until the improvement of clinical symptoms. Timepoint: The first day of study and the day of discharge from the corona ward. Method of measurement: Clinical examination (using patient record).;Duration from the start of the study until the improvement of paraclinical symptoms. Timepoint: The first day of study and the day of discharge from the corona ward. Method of measurement: using patient record.

Secondary Outcome Measures